Drug Trial Radar · NCT01861522
The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
473
Actual
Start
Apr 2013
Primary completion
Dec 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- May 23, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 7 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis and to investigate safety of TAU-284.
Conditions
- Perennial Allergic Rhinitis
Interventions
Bepotastine besilateDrug
Two TAU-284 5mg tablets will be taken orally twice a day
PlaceboDrug
Two Placebo tablets will be taken orally twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]Time frame: Baseline and Week 2
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Reserch site
Fukuoka, Japan
Reserch site
Toyama, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.